HC Wainwright Has Positive Outlook for TBPH Q2 Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities researchers at HC Wainwright raised their Q2 2026 EPS estimates for shares of Theravance Biopharma in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings of $0.19 per share for the quarter, up from their previous estimate of ($0.19). HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s Q3 2026 earnings at $0.28 EPS, Q4 2026 earnings at $2.02 EPS and FY2026 earnings at $2.37 EPS.

A number of other equities analysts also recently commented on the stock. B. Riley Financial reissued a “neutral” rating and issued a $14.00 price objective (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday. Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday. Wall Street Zen lowered Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. BTIG Research decreased their price objective on Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $22.60.

Theravance Biopharma Stock Performance

NASDAQ TBPH opened at $13.57 on Friday. The company has a market cap of $687.59 million, a PE ratio of 23.81 and a beta of 0.17. The firm’s 50 day moving average price is $18.95 and its 200-day moving average price is $16.83. Theravance Biopharma has a 52-week low of $7.90 and a 52-week high of $21.03.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the last quarter. Creative Planning grew its stake in Theravance Biopharma by 6.7% during the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 842 shares during the last quarter. State of Wyoming increased its position in Theravance Biopharma by 5.7% during the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after buying an additional 1,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Theravance Biopharma by 6.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 1,020 shares during the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma News Summary

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: HC Wainwright sharply raised FY‑2026 and quarterly EPS forecasts and keeps a Buy rating and $27 target, signaling materially improved earnings expectations that could support a rebound. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Zacks highlights the stock as deeply oversold after a ~30% four‑week decline and notes analyst upward estimate revisions, arguing the pullback may be a buying opportunity for a technical reversal. Zacks: Buy the dip
• Neutral Sentiment: Market context: TBPH is trading with above‑average volume, inside its 1‑year range ($7.90–$21.03) and below the 50‑day moving average — a mixed technical picture that increases sensitivity to news flow.
• Negative Sentiment: Theravance reported a late‑stage drug trial failure that prompted a sharp share decline and workforce reductions, a material fundamental negative that reduces near‑term upside. Share tumbles and jobs to go after Theravance failure
• Negative Sentiment: Management is reportedly considering a possible sale after the trial setback, which introduces strategic uncertainty and potential valuation pressure while options are explored. MSN: Possible sale after trial setback
• Negative Sentiment: Oppenheimer downgraded TBPH from Outperform to Market Perform, signaling reduced near‑term conviction from a major bank and likely contributing to selling pressure. Oppenheimer downgrades Theravance
• Negative Sentiment: BTIG issued a pessimistic forecast for the stock, adding to negative analyst sentiment and raising downside risk until clarity on the pipeline or strategic actions emerges. BTIG pessimistic forecast

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.